Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

Trial Details

NCT ID
NCT06551584
Phase
PHASE1
Sponsor
Stanford University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ORCA-T
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

  • Eligible diseases:
  • Acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) as defined in Secti…
  • Myelodysplasic syndrome (MDS) myelodysplastic syndromes eligible for alloHSCT and/or treatment-related MDS \<10% blasts
  • Age ≥ 18 and ≤ 70 years at the time of enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →